| IELSG50 | Pembrolizumab and radiotherapy for previously untreated patients with limited-stage NK/T cell lymphoma who are not eligible for chemotherapy |
| Participants required | 30 |
| Investigator responsible(s) | S. Luminari and W. Zhao |
| Objective(s) | The primary objective of the IELSG50 trial is to test the efficacy of concurrent RT- Pembrolizumab in patients with limited-stage high-risk NK/T cell lymphoma who are not eligible or refuse to receive chemotherapy. |
| Lay summary | Nasal NK/T cell lymphoma is a rare non-Hodgkin’s lymphoma associated with the Epstein-Barr virus and common in Asian and South American populations. It often affects areas such as the nose, skin or digestive tract and can be difficult to treat in high-risk patients. Radiation therapy (RT) shows good local results, and new drugs such as pembrolizumab offer promising low-toxicity options. High-risk patients who can’t tolerate or refuse chemotherapy may benefit from a combination of RT and pembrolizumab. This combined approach is being studied as a potential first-line treatment to improve outcomes in high-risk cases with localized disease |